People · Operator
Named in public records as an officer, director or promoter · active 2014–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Harpoon Therapeutics, Inc. | — | Biotechnology | Series D+ | $220.3M | $1.4B | 2023 |
| VelosBio Inc. | — | Biotechnology | Series D+ | $210.5M | $5.6B | 2018 |
| Sorriso Pharmaceuticals, Inc. | — | Biotechnology | Series B | $21.3M | $448.9M | 2021 |
| Optikira, LLC | — | Pharmaceuticals | Series A | $8.8M | $83.6M | 2014 |
Mark Chin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Chin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Alan Colowick | 2 | 7 |
| David Johnson | 1 | 35 |
| Edward Mathers | 1 | 12 |
| Michael Grey | 1 | 10 |
| Scott L. Glenn | 1 | 9 |
| Baiju Shah | 1 | 8 |
| Cam Gallagher | 1 | 7 |
| MIN CUI | 1 | 5 |
| Jayson Punwani | 1 | 3 |
| Susan Dube | 1 | 3 |
| Gerald McMahon | 1 | 3 |
| Luke Walker | 1 | 3 |
| Langdon Miller | 1 | 2 |
| Theodore Torphy | 1 | 2 |
| Joseph Bailes | 1 | 2 |
| Andrew Robbins | 1 | 2 |
| Richard Vincent | 1 | 2 |
| Scott Myers | 1 | 2 |
| Ron R. Hunt | 1 | 2 |
| Jonathan Drachman | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.